INCY Incyte
- 68.550
- -2.280-3.22%
- 68.550
- 0.0000.00%
Incyte News
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $82
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
Incyte (NASDAQ:INCY) Shareholders Have Lost 22% Over 5 Years, Earnings Decline Likely the Culprit
BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $52
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86
TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)
Incyte's Growth Prospects Hampered by Pipeline Setbacks and Market Challenges
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Positive Outlook on Incyte's Stock: InMIND Study Validates Tafasitamab Combination Efficacy and Safety
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Market Falls Wednesday, but Googles Chip Impresses | WST
Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Incyte Says Phase 3 InMIND Trial Met Primary Endpoint of PFS
Express News | Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Incyte's BET Inhibitor Program Holds Promise Amid Safety Concerns and Strategic Uncertainty
No Data
